drugset / Trial / NCT00206518
Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to learn if the biomarker information obtained (learned or received) from the earlier studies can tell us whether or not Taxotere and/or Adriamycin/Cytoxan can cause tumors to become smaller.
Timeline
- Start
- 2004-09
- Primary completion
- 2016-10
- Completion
- 2016-10-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cyclophosphamide | Other / unclassified | 600 mg/m2 | — |
| Subject | Docetaxel | Small molecule | 100 mg/m2 | — |
| Subject | Doxorubicin | Other / unclassified | 60 mg/m2 | — |